← Back to Clinical Trials
Recruiting Phase 2 NCT05417776

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Trial Parameters

Condition Interstitial Lung Disease
Sponsor Massachusetts General Hospital
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 30
Sex ALL
Min Age 40 Years
Max Age N/A
Start Date 2022-09-28
Completion 2026-04-01
Interventions
[68Ga]CBP8Dotarem

Brief Summary

The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.

Eligibility Criteria

Inclusion Criteria: Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8) * Age greater than 40 years * Have the ability to give written informed consent * First degree relative of a family member with pulmonary fibrosis * No known history of interstitial lung disease * No tobacco use within the prior 6 months. Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22) * Age greater than 40 years * Have the ability to give written informed consent * ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern) * No tobacco use within the prior 6 months. Exclusion criteria: * Electrical implants such as cardiac pacemaker or perfusion pump * Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or

Related Trials